The Modernization of Cosmetics Regulation Act, known as MoCRA, is the most significant change to United States cosmetics regulation in more than eighty years. It was enacted at the end of 2022 and it moves the US framework much closer to the European model, in which a named party holds a technical file and is answerable for safety rather than relying on the absence of pre-market approval.
The part that surprises most brand owners is where the obligations sit. MoCRA places most of the new duties on the responsible person, which for an imported private label product is usually the brand or the importer whose name appears on the label, not the overseas factory. That means a brand cannot discharge its obligations simply by buying from a compliant manufacturer.
This guide is written for brand owners and sourcing managers who are launching or continuing to sell cosmetics in the United States. It covers the practical duties, the documents to request from your OEM partner, and the differences from the EU and Chinese systems that affect the same product.
One important caveat before the detail: FDA has adjusted implementation timelines and issued guidance during the rollout, and the position continues to develop. Treat this as a planning framework and confirm the current requirements with FDA guidance or your regulatory adviser before filing.
What MoCRA changes for a cosmetic brand
Five obligations define the new landscape for a typical skincare or colour cosmetics brand selling into the United States.
Facility registration applies to facilities that manufacture or process cosmetic products for distribution in the United States. Product listing applies to each cosmetic product, and requires an ingredient statement and other product information to be filed. Safety substantiation requires the responsible person to hold adequate evidence that the product is safe under labelled or customary conditions of use. Adverse event reporting requires serious adverse events to be reported to FDA within a defined window. And the labelling framework is being tightened, including on fragrance allergens and on products intended for professional use.
Alongside those, MoCRA directed FDA to study or regulate specific areas including talc testing, per- and polyfluoroalkyl substances, and good manufacturing practice. The practical effect is that a brand should expect the compliance workload to grow rather than settle.
Who is the responsible person, and what does that mean for an import brand?
Under MoCRA the responsible person is broadly the manufacturer, packer or distributor whose name appears on the label of a cosmetic product. For a private label brand importing from an overseas factory, that is normally the brand itself.
This single definition explains most of the practical consequences. The brand, not the factory, holds the safety substantiation file. The brand, not the factory, receives and reports serious adverse events. The brand, not the factory, files the product listing, although it will depend on the manufacturer for the information needed to file it.
A contract manufacturer's FDA registration is real and necessary, but it does not transfer the brand's obligations. When a brand asks us whether a compliant factory means a compliant product, the answer is no, and that distinction is worth building into the project plan at the start rather than discovering during a retailer audit.
Facility registration and product listing: what has to be filed
Registration is the manufacturer's or processor's duty. Each facility that manufactures or processes cosmetics for US distribution must be registered with FDA, and the registration has to be renewed periodically. A brand should hold a current registration confirmation from each factory it uses, including any contract filler used for a specific format.
Listing is the responsible person's duty. Each cosmetic product is listed with FDA, together with the facility or facilities where it is manufactured and an ingredient statement. In practice the brand collects the data from the factory and files it, and the factory needs to supply accurate ingredient declarations, including any fragrance components that are subject to disclosure, plus the facility registration number.
Two practical problems arise repeatedly. First, listing is per product, not per formula, so a brand selling the same liquid under three brand names or three pack sizes needs to think carefully about what counts as a distinct product. Second, ingredient statements have to be accurate and current, which means that any reformulation requires an updated listing rather than a passive update. Building a change control process around the listing is the cheapest way to avoid a compliance gap later.
Safety substantiation: what evidence you need to hold
Safety substantiation is the obligation most often underestimated, because it does not require a filing at the moment of launch but does require the brand to be able to produce evidence on request.
In practice, adequate substantiation for a cosmetic normally means a documented safety assessment supported by the toxicological profile of each ingredient at the concentration used, the exposure assumptions for the product type and application site, and any testing specific to the product. That is the same body of reasoning that a European Cosmetic Product Safety Report contains, and a brand selling in both markets can often work from one underlying technical dossier with market-specific adaptations.
For a brand buying private label, the critical question to ask the factory is what safety documentation comes with the formula. A specification sheet alone is not safety substantiation. What is needed is an assessment that addresses the finished formula, and it has to be current with respect to the formula actually being manufactured.
Where a product makes a stronger claim, for example a sunscreen claim or a claim that would bring it within the drug framework, the evidentiary bar rises well above what a cosmetic requires, and the regulatory pathway changes entirely.
Adverse event reporting and the compliance process behind it
Serious adverse events must be reported to FDA within a defined window, and the obligation sits with the responsible person. A serious adverse event in this context is not every case of irritation; the threshold is set at events that result in significant outcomes such as hospitalisation, disfigurement or a medical intervention.
The operational implication is that a brand needs a complaint intake process that can recognise a reportable event, capture the required information, and escalate it on a timeline rather than on a best-effort basis. In our experience this is the single most commonly missing piece of compliance infrastructure in small beauty brands, and it is inexpensive to put in place before launch rather than after a complaint arrives.
Adverse event records also have to be maintained, which means the process should be documented and auditable rather than informal. A simple log with defined fields, a documented triage rule and a named owner covers most of the requirement for a small brand.
GMP expectations and how they interact with an overseas factory
MoCRA directed FDA to establish good manufacturing practice requirements for cosmetics, which will formalise the standards that many factories have been following voluntarily, often under the international standard for cosmetic good manufacturing practice or the ISO framework.
For a brand, the practical approach is to request evidence of the factory's quality system rather than to assume it. What is worth holding on file: the factory's quality certifications and audit reports, its product specification and batch record structure, its microbiological and stability testing protocols, its raw material supplier qualification process and its deviation and recall procedures.
Two points matter particularly for import brands. First, documentation should be in English or accompanied by a certified translation, because a safety file that no one can read does not support substantiation. Second, the brand should verify that the batch documentation for its own product is being retained and can be produced, since a batch record is the evidence that the product on the market is the product that was assessed.
Labelling: ingredient naming, fragrance allergens and professional use
US labelling follows its own conventions, and an artwork file prepared for the European market cannot simply be reused. Ingredient naming conventions differ, the order of declaration rules differ, and the treatment of certain ingredients is different.
Fragrance allergen disclosure is an area where MoCRA anticipated further rulemaking, and brands with fragrance in their formulas should plan for a level of allergen transparency that is closer to the European approach than the historical US position. Designing artwork with the space for that disclosure now is cheaper than redesigning later.
MoCRA also addressed products intended for professional use, which affects how a product must be labelled and how it may be marketed. A brand selling into a salon or clinic channel should confirm whether its product falls into that category, because the labelling and the intended-use statements differ from a retail product.
Talc, PFAS and the studies that follow MoCRA
MoCRA directed FDA to work on several specific issues beyond the core obligations, and two of them affect product development decisions.
For talc, FDA was directed to establish a standardised testing method for asbestos, which means a brand using talc in a pressed powder or a body product should expect to hold supplier documentation on asbestos testing as a matter of course. Requesting an asbestos testing statement with each talc lot is now normal practice rather than belt-and-braces.
For per- and polyfluoroalkyl substances, FDA was directed to assess their use in cosmetics, and several states have moved independently to restrict PFAS in cosmetics. A brand with a long-wear or water-resistant claim should review its supply chain for PFAS, since these substances have historically appeared in some film-forming and water-repellent systems, and the restrictions are tightening rather than loosening.
The small business exemption, and why it may not cover you
MoCRA includes a small business exemption from the registration and listing requirements for responsible persons and facilities below a defined sales threshold, which is adjusted for inflation.
The exemption is narrower than many brands assume, and two features matter. First, it applies to some obligations but not others; safety substantiation and adverse event reporting are not exempt in the same way, so a small brand still needs those capabilities. Second, the exemption does not cover certain product categories, which have historically included products intended for use in the eye area, products that alter appearance for an extended period, and products that are also drugs. A brand selling an eye product or a long-wear cosmetic should not assume it qualifies.
Testing eligibility against the current threshold and the current product-category list is a five-minute exercise that prevents an expensive assumption. We advise brands to document the eligibility decision even when the conclusion is that the exemption applies, because the reasoning itself is the evidence.
What to request from your OEM manufacturer
A practical document request list for a MoCRA-ready project includes: the facility registration confirmation with its registration number, the full ingredient declaration with concentrations for the safety assessment, the fragrance allergen breakdown if fragrance is used, the safety substantiation package for the finished formula, stability and microbiological challenge reports, pack compatibility reports, batch records retention policy, the quality certifications and audit history, and a statement on any talc or PFAS content along with relevant supplier testing.
We provide this documentation set as part of a project rather than as a separate commercial negotiation, because a product that cannot be documented cannot be sold in the United States at all. Brands building a launch calendar should allow for the documentation to be assembled alongside the samples rather than after the artwork is printed.
How MoCRA compares with the EU and China
| Element | United States (MoCRA) | European Union (1223/2009) | China (CSAR) |
|---|---|---|---|
| Named accountable party | Responsible person on the label | Responsible person established in the EU | Registrant or filer in China |
| Pre-market notification | Listing after launch | CPNP notification before placing on market | Filing or registration, in some cases before sale |
| Safety file | Substantiation held, produced on request | Cosmetic Product Safety Report plus Product Information File | Safety assessment required for filing and registration |
| Manufacturing standard | GMP rules being established | ISO 22716 expected | GMP requirements under CSAR |
| Ingredient restrictions | Prohibited and restricted lists plus colour additive rules | Annex lists with detailed restrictions | Approved ingredient inventory with use conditions |
| Special categories | Drug framework for some claims | Cosmetic only, claims tightly controlled | Special cosmetics registration for defined claim types |
| Animal testing | Not banned at federal level | Testing ban for cosmetic ingredients | Testing required for some categories |
Looking at the table sideways explains a common experience: a formula that is straightforward to sell in one market can require a different pigment set, a different claim set and an additional test package in another. We recommend brands decide their priority market first and harmonise the rest around it, rather than attempting to build a single product that satisfies every framework simultaneously.
Frequently asked questions about MoCRA and cosmetic sourcing
Does a compliant overseas factory make me compliant?
No. Facility registration is the factory's duty, but product listing, safety substantiation and adverse event reporting sit with the responsible person, which is normally the brand. Both sides have obligations, and they are different obligations.
Do I need to register a cosmetic product before selling in the US?
Cosmetics do not require pre-market approval in the same way as drugs, and the listing framework operates alongside the market introduction rather than as a gate. Confirm the current filing expectations and timelines against FDA guidance for your product type.
Do I need a US agent or establishment?
The responsible person must be reachable and answerable under the framework, and could be the brand, the importer or another party whose name appears on the label. The practical requirement is a clearly identified accountable party with the technical file in hand.
Can you provide the safety documentation for the formula you manufacture?
Yes. Formula safety documentation, stability reports, microbiological challenge reports, pack compatibility reports and ingredient documentation are part of a standard project, and we provide them in English so they can support a US filing.
Does MoCRA mean I have to reformulate?
Not automatically. The changes are mostly about documentation, labelling and process rather than about prohibited ingredients, although the work on PFAS and on talc testing can affect specific formulas. A formula review against the current restrictions is a sensible first step.
Next step: plan the documentation before the artwork
If you are launching a skincare or colour cosmetics product in the United States, send us the format, the target market and your timeline and we will confirm what documentation the project can supply, flag any formula decisions that MoCRA affects, and provide a costed quote for the manufacture. Write to capsulebiotech@163.com, message the right team on WhatsApp: Capsule Series (capsules only) +86 158-7655-5319, Cosmetics Series (serum, hair care, body care, fragrance) +86 158-7655-5319, or use the inquiry form and we will reply within one working day.
Related programmes and guides: hydrating soothing repair face cream, amino acid facial cleanser, and long-lasting waterproof sweat-proof foundation.